Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus induction chemotherapy, concurrent chemoradiotherapy and maintenance in high-risk locally advanced nasopharyngeal carcinoma
ChiCTR2200062794Phase 2Not yet recruiting
- Sponsor
- Army Specialized Medical Center
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in nasopharyngeal carcinoma (NPC), sponsored by Army Specialized Medical Center. Primary endpoint: 9-week complete response rate. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2200062794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062794.